Back

Mitochondrial function and oxidative stress in isolated peripheral blood mononuclear cells and trastuzumab-induced cardiotoxicity: a prospective longitudinal study

25 August 2023 (17:15 - 18:00)
Organised by: Logo
Congress Presentation Part of: Basic research in cardio-oncology Cardio-Oncology ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Doctor Krit Leemasawat

Chiang Mai University, Chiang Mai (Thailand)

6 More presentations in this session

Presentation thumbnail
Biomimetic nanozymes target the heart to suppress ferroptosis for ameliorating doxorubicin-induced cardiotoxicity via synergetic effect of antioxidant stress and Nrf2/Hmox1 inhibition
Professor T. Liu (Tianjin, CN)
Abstract Slides Video
Presentation thumbnail
Induced pluripotent stem cell-derived cardiac myocytes to assess anthracycline cardiotoxicity
Professor L. Van Aelst (Leuven, BE)
Abstract Slides Video
Presentation thumbnail
Cardiovascular events following vascular endothelial growth factor inhibitor therapy with sunitinib or pazopanib in patients with renal cell carcinoma - a nationwide registry-based follow-up study
Doctor J. Shanmuganathan (Aalborg, DK)
Abstract Slides Video
Presentation thumbnail
Circulating SerpinA3 as a novel indicator of cardiovascular dysfunction after anthracycline chemotherapy
Doctor H. Boen (Edegem, BE)
Abstract Slides Video
Presentation thumbnail
Protective effects of nicotinamide mononucleotide on radiation-related cardiac injury
Professor T. Liu (Tianjin, CN)
Abstract Slides Video

Access the full session

Session thumbnail
Basic research in cardio-oncology

The Event

Event poster

ESC Congress 2023

25 August 2023 17:15 CET
You may be interested in
thumbnail
Congress Presentation
Dysfunctional high-density lipoproteins in breast cancer patients and tumor-bearing mice treated with chemotherapy
thumbnail
Congress Presentation
Changes in blood metabolomes as potential biomarkers for severity and prognosis in doxorubicin-induced heart failure: a study in HER2-positive and HER2-negative breast cancer patients
thumbnail
Congress Presentation
The risks of continuing trastuzumab treatment in HER-2 positive breast cancer after the development of asymptomatic left ventricular dysfunction

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources